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a b s t r a c t
The ability of tumor cells to leave a primary tumor, to disseminate through the body, and to ultimately
seed new secondary tumors is universally agreed to be the basis for metastasis formation. An accu-
rate description of the cellular and molecular mechanisms that underlie this multistep process would
greatly facilitate the rational development of therapies that effectively allow metastatic disease to be
controlled and treated. A number of disparate and sometimes conﬂicting hypotheses and models have
been suggested to explain various aspects of the process, and no single concept explains the mechanism
of metastasis in its entirety or encompasses all observations and experimental ﬁndings. The exciting
progress made in metastasis research in recent years has reﬁned existing ideas, as well as giving rise
to new ones. In this review we survey some of the main theories that currently exist in the ﬁeld, and
show that signiﬁcant convergence is emerging, allowing a synthesis of several models to give a more
comprehensive overview of the process of metastasis. As a result we postulate a stromal progression
model of metastasis. In this model, progressive modiﬁcation of the tumor microenvironment is equally
as important as genetic and epigenetic changes in tumor cells during primary tumor progression. Mutual
regulatory interactions between stroma and tumor cellsmodify the stemness of the cells that drive tumor
growth, in amanner that involves epithelial–mesenchymal andmesenchymal–epithelial-like transitions.
Similar interactions need to be recapitulated at secondary sites for metastases to grow. Early disseminat-
ing tumor cells canprogress at the secondary site in parallel to the primary tumor, both in terms of genetic
changes, as well as progressive development of a metastatic stroma. Although this model brings together
many ideas in the ﬁeld, there remain nevertheless a number of major open questions, underscoring the
need for further research to fully understand metastasis, and thereby identify new and effective ways of
se.treating metastatic diseaAbbreviations: BMDC, bone marrow-derived cell; CAF, carcinoma-associated
broblast; CGH, comparative genomic hybridization; CSC, cancer stem cell; CTC, cir-
ulating tumor cell; DTC, disseminated tumor cells; ECM, extracellular matrix; EMT,
pithelial–mesenchymal transition; FAK, focal adhesion kinase; mCSC, migrating
ancer stem cell; MET, mesenchymal–epithelial transition; TAM, tumor-associated
acrophage.
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1. Introduction
Ever since metastasis has been investigated, models and con-
cepts about how the metastatic disease process works have been
suggested [1]. These have provided a framework within which
to understand clinical observations and experimental ﬁndings,
have served as an important tool for directing further research,
and have suggested how new therapies that address metastatic
disease might be developed. Most early concepts were based
on clinical observations and autopsy ﬁndings. These include the
“seed and soil” hypothesis that envisages tumor cells as seeds that
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urvive outside of the primary tumor and grow as metastases [2],
he anatomical/mechanical model that proposes that patterns of
etastasis can be explained by the location of the primary tumor
ith respect to the blood and the lymphatic vasculature, which in
urn determines to which organs disseminating tumor cells will
e transported and subsequently become mechanically entrapped
3,4], and theories about metastatic cascades and generalizing sites
hat hold that metastases in one organ could disseminate tumor
ells and give rise to metastases in further organs in a sequential
anner [5,6].
The  complexity of metastasis as a process determines that
one of these or indeed other concepts completely and accurately
escribes how the process works, nor do they integrate and encom-
ass all clinical observations and experimental ﬁndings. This can
ave major consequences for therapy. For example, Halstead’s rad-
cal mastectomy for the treatment of breast cancer in which the
xilla and its lymph nodes are removed in addition to the breast
ontaining the primary tumor was developed on the basis of the
etastatic cascade concept. The rational was that if lymph nodes
ontaining metastatic tumor cells were left in situ, then these lymph
ode metastases could themselves give rise to metastases in other
rgans. Removing all lymph nodes in the axilla should therefore
mprove survival rates. However, large-scale long-term random-
zed trials have provided evidence in recent years that for a number
f types of cancer removing the lymph nodes that drain primary
umors has very little effect on patient survival [7]. Furthermore,
ecent analysis of the growth rate of tumors suggests that within
he lifetime of a cancer patient there is not enough time for the serial
eeding of metastases from a metastasis elsewhere [8]. Together,
hese observations underline the importance of an integrated and
ccurate concept of how metastasis works, if efﬁcient and effective
herapies are to be developed.
In the last few years, rapid progress has been made in many
reas of metastasis research. These new insights into the process
f metastasis have challenged existing accepted paradigms, stim-
lated the development of new concepts and models, expanded
ur understanding of hitherto poorly understood aspects of the
rocess, and have highlighted the need to re-evaluate and inter-
ret existing data in the light of these new ﬁndings. In this review,
e discuss long-standing concepts about how metastasis devel-
ps in the context of some of the contemporary theories that have
risen recently as a consequence of these new observations. We
se the concept of the metastatic “seed” and the “soil” of the organ
icroenvironment – the most long-lasting and inﬂuential hypoth-
sis in the ﬁeld – as a framework within which to discuss these
deas.
. How does the metastatic seed develop?
.1. Clones, heterogeneity and selection
Based on a series of seminal observations in experimental ani-
als [9,10], Fidler and others formulated the clonal selection model
o explain how tumor cells acquire the ability to metastasize.
his model postulates that during tumor progression, increasing
enomic instability in the primary tumor results in the stochas-
ic accumulation of genetic and epigenetic defects, resulting in a
eterogeneous population of tumor cells that differ in their gene
xpression patterns. The gene expression proﬁle of some of these
ells will be sufﬁcient to endow this subpopulation with the prop-
rties required for local invasion, survival in the circulatory system,
xtravasation into secondary organs, and growth as overt metas-
ases at these sites. Other subpopulations of cells in the primary
umor will have some of the properties required, but will not suc-
essfully complete all the necessary steps. Thus tumor cells thater Biology 22 (2012) 174– 186 175
successfully  form metastases should be considered as “decathlon
winners” [10].
In  addition to experimental evidence from animal models, sup-
port for the clonal selection theory comes from histological and
genetic analysis of human tumors which provides evidence for het-
erogeneous patterns of gene expression [11]. A corollary of the
clonal selection theory is that organ-speciﬁc patterns of metas-
tasis may  be dependent on tumor-intrinsic properties that are
selected for as tumor cells disseminate. Initial evidence for the
existence of genes driving organ-speciﬁc metastasis came from the
identiﬁcation of poor prognosis gene signature through supervised
clustering of cohorts of primary breast cancers [12–15]. Subse-
quently, gene expression signatures associated with breast cancer
metastasis to bone, lung and brain were deﬁned in experimen-
tal models and validated with human samples [16–18]. These
experimental studies were based on the generation and analy-
sis of organotropic metastatic lines derived from a parental line
(mostly MDA-MB-231) by multiple rounds of in vivo selection. The
brain and lung metastasis signature were partly overlapping and
contained genes controlling vascular remodeling and permeabil-
ity, such as COX2, ANGPTL4, LTBP1 and EGFR ligands. The bone
metastasis signature was  rather divergent, and contained genes
associated with bone osteolysis and cell survival in the bone such as
IL-11, PTHrP and OPN. Besides allowing the identiﬁcation of indi-
vidual genes, these studies proved useful for the classiﬁcation of
metastasis-promoting genes based on their functional contribution
to metastasis. Three categories were deﬁned: (i) metastasis-
initiating genes, comprising genes that provide an advantage in
tumor cell growth, escape and invasiveness at the primary tumor
site; (ii) metastasis virulence genes, giving survival advantages to
disseminated tumor cells within the newly colonized microen-
vironment; (iii) genes promoting progression, giving advantages
during the entire metastatic process by affecting general steps, such
as tumor angiogenesis, inﬂammation, epithelial–mesenchymal
transition  (EMT), or immune evasion. While these studies have
provided unprecedented molecular details on the mechanisms of
organ-speciﬁc metastasis, many questions that are relevant for
the development of therapeutic strategies remain open. For exam-
ple, the experimental models are based on the use of human cell
lines in immunosuppressed mice, thereby bypassing a possible
role of the adaptive immune system in controlling metasta-
sis. Also, cancer cells were injected directly into the vascular
system in these models, thus mimicking only the ﬁnal steps
of metastasis.
The clonal selection theory would not seem consistent with the
observation that primary tumors are often phenotypically simi-
lar to the metastases they give rise to [19], as according to this
model, metastases should represent selection of only a subpop-
ulation in the primary tumor. Other observations, for example
from gene expression proﬁling of primary tumors, also suggest
that the clonal selection model may  need to be re-evaluated [20].
These studies have deﬁned molecular signatures in primary tumors
that successfully predict patient prognosis. The majority of tumor
cells in the primary tumor must express the signature for it to
be detected, which does not seem to conform with the notion
that a small subpopulation of tumor cells develop metastastic
properties, as suggested by the clonal selection hypothesis. These
data rather indicate that metastatic development is pre-deﬁned
by genetic changes acquired during the initial stages of tumor
development. Consistently, transcriptome analysis suggests that
primary tumors are rather similar to their matched metastases,
and are more similar with each other than with tumors from
other individuals [21]. Nevertheless, a number of observations
make it difﬁcult to use transcriptome analysis to draw conclu-
sions about the provenance of the tumor cells that seed metastases
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umors and their matched metastases also display profound differ-
nces in their gene expression proﬁles [8,22]. The different genetic
ackgrounds of individuals may  account for the more extensive dif-
erences between individuals than between their metastases and
heir primary tumors. Moreover, recent studies suggest that pri-
ary tumors are composed of clonal areas, which would not be
etected by studies that simply take total tumor material for anal-
sis [23]. Furthermore, the existence of a predictive ‘metastatic
ignature’ in primary tumors might not be inconsistent with the
lonal selection theory, since metastatic tumor cells may  self-seed
ack to the primary tumor and therefore ‘contaminate’ a primary
umor signature with a metastatic signature [24,25]. Self-seeding
f the primary tumor with metastasis-derived cancer cells might
lso complicate the interpretation of the established relationship
etween primary tumor size and metastatic potential [26,27].
Variations  on the clonal selection model have been proposed
hat help to resolve some of these issues. The clonal dominance
odel suggests that metastatically competent cells have a com-
etitive advantage and therefore outgrow other subpopulations in
he primary tumor [28]. The dynamic heterogeneity model sug-
ests that the acquisition of metastatic competence may  only be
ransient, and that the frequency with which metastatically com-
etent cells arise determines the metastatic potential of a given
umor [29].
.2.  Is the dissemination of the metastatic seed an early or late
vent  in the life of a tumor?
Implicit  in the clonal selection theory and its variants is the
dea that cancer cells need to accumulate a sufﬁcient number of
enetic and epigenetic alterations to acquire full metastatic capac-
ty, requiring that metastasis is a rather late event during tumor
rogression to allow the accumulation of such alterations [30].
his notion is consistent with the generally accepted correlation
etween primary tumor size and risk of lymph node and distant
etastasis [27], and the observation that metastatic genes are
lready expressed in primary tumors [31].
In the last few years a signiﬁcant body of evidence has emerged
hich indicates that tumor cells that ultimately form metastases
ay disseminate very early after tumorigenesis. This notion is
ased on the genomic analysis of single disseminated tumor cells
DTCs), as well as matched primary tumors and their metastases
rom human patients [8,22]. Similarly, experimental manipulation
f animal models of metastasis suggests that dissemination may
ccur even at pre-malignant stages of tumorigenesis [32]. Con-
istently, circulating tumor cells (CTCs) in the blood and DTCs in
he bone marrow can both be detected at early stages of tumor
evelopment in cancer patients [30,33–37]. To accommodate these
bservations, an alternative model has been proposed in which
umor cells disseminate early during tumor progression, and sub-
equently acquire additional genetic changes that ultimately allow
hem to grow out as metastases at the distant site. In this model,
rimary tumors and metastases progress in parallel as indepen-
ent lesions [8]. Clonal selection in primary tumors and metastases
ould be compatible with this model, but would not be a piv-
tal determinant of when dissemination of the metastatic seed
ccurs.
The comparative genomic analysis of DTCs from lymph node
nd bone and their corresponding primary tumors has been
erformed using comparative genomic hybridization (CGH) for
 number of types of cancer, and provides signiﬁcant evidence
n support of a parallel progression model. For example, DTCs
enerally show fewer genetic abnormalities than their primary
umors and there is also extensive disparity between chromosomal
ains and losses when DTCs and their primary tumors are com-
ared (reviewed in [8,22]). These studies also provide evidenceer Biology 22 (2012) 174– 186
that  genetic abnormalities in DTCs were acquired independently
of those in the primary tumor, and that substantial numbers of
chromosomal losses were found in primary tumors that were not
present in DTCs. As loss of DNA is irreversible and transmitted
to progeny, these observations provide evidence for both early
dissemination of metastatic founder cells and parallel progression.
However, studies on DTCs are potentially complicated by the
use of epithelial markers to detect them. Tumor cells undergoing
EMT, for example (see below), may  not express these markers
and therefore would not be included in the analysis, potentially
skewing the results. Nonetheless, when matched primary breast
tumors and their metastases were also compared genomically,
for example using CGH, almost half of the paired samples showed
more discordances than shared chromosomal abnormalities, and
a substantial number of chromosomal losses were found in the
primary tumors that were not present in the metastases [38].
Similar ﬁndings have been made in other studies [39,40].
In  addition to this genomic analysis, other evidence also sup-
ports the notion of early dissemination and parallel progression.
DTCs may  remain dormant over prolonged periods of time, and
a recent study demonstrated in vivo evolution in dormant tumor
cells of the heritable ability to escape dormancy and grow out
as metastases [41]. Experimentally, when untransformed mam-
mary epithelial cells containing inducible oncogenes are injected
intravenously, they can remain viable in lung tissue for prolonged
periods of time before assuming malignant growth upon induc-
tion of oncogene expression [42], providing a proof of principle
that even non-transformed disseminated cells have the potential
to remain dormant and ultimately grow as tumors. Nevertheless,
given that the deﬁnition of malignancy is the breaching of the base-
ment membrane, it is currently difﬁcult to envisage how tumor
cells could physically disseminate at a pre-malignant stage, as has
been suggested [32]. However, recent studies show that invasive-
ness may  appear early during transformation in cells that escape
oncogene-induced senescence [43], providing a mechanism for dis-
semination very early during tumorigenesis.
Genomic exon sequencing of colorectal [44] and pancreatic pri-
mary tumors and their matched metastases [23] revealed that
the majority of point mutations were common to both primary
tumors and their metastases, and that metastases had acquired a
few additional mutations. This may  argue against early dissemina-
tion. Indeed, these data were used to calculate when the metastastic
founder cells developed, and concluded that few if any additional
mutations are required for metastastic founder cells to develop
from carcinomas [44], and that metastatic dissemination is a late
event [23]. However, there are some important caveats associated
with the interpretation of these ﬁndings. Exon analysis of protein-
encoding genes was  used, which by deﬁnition only addresses
around 1% of the genome [45]; analysis of the genomes of pri-
mary tumors and their matched metastases on a more global level
comes to different conclusions (see above). Furthermore, the anal-
ysis of point mutations in protein-encoding genes may  skew the
investigation toward genetic changes that underlie the tumorigenic
properties of the cancer cells. Thus patterns of point mutations
would be expected to be similar between primary tumors and their
metastases, and these data sets may  not be appropriate for making
robust conclusions about the etiology of metastatic founder cells.
In addition, disparity in point mutations between primary tumors
and their metastases that were found in other studies support the
notion of parallel progression [22].
2.3. Metastatic seeds and the pecking order: hierarchy and CSCsAnother  concept for how metastasis works arises as a corol-
lary of the cancer stem cell (CSC) hypothesis that predicts that
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y a hierarchical organization, with stem-like cells endowed with
elf-renewal and the capacity to differentiate, but also with more
ommitted progenitor cells and fully differentiated lineages [46].
s by deﬁnition CSCs are predicted to be the cells that initiate and
rive secondary tumor growth, they would be expected to underlie
alignant behavior by responding to environmental cues to detach
rom the primary tumor and disseminate throughout the body as
o-called migrating cancer stem cells (mCSCs) [19]. Thus mCSCs are
redicted to be the metastatic seeds that found secondary tumors.
Experimental evidence to support the notion that CSCs play a
ritical role in metastasis remains thin on the ground. However,
ecent studies point to the existence of speciﬁc stem-like subpopu-
ations of cancer cells endowed with high migratory and metastatic
apacity, and suggest that CSCs are heterogeneous populations that
nclude actively cycling CSCs that drive tumor growth, as well as
ore quiescent stem-like cancer cells. This cellular heterogene-
ty within the CSC compartment with the dichotomy of cycling
nd quiescent CSCs was ﬁrst studied in pancreas cancer where
he CSC population is deﬁned by CD133 expression. The combined
xpression of CD133 and CXCR4, a chemokine receptor implicated
n cellular migration and high malignant and metastatic potential,
armarks CTCs detectable in the portal vein which eventually form
iver metastasis [47]. Accordingly, depletion of the migrating cancer
tem cells using a pharmacological inhibitor of the CXCR4 receptor
brogated their metastatic potential [47]. CXCR4 expression in CSCs
s likely to make them responsive to a chemotactic gradient estab-
ished by its speciﬁc ligand, stromal factor 1 or SDF-1, expressed by
everal organs in which metastases develop.
Additional evidence for the existence of different CSCs subtypes
esponsible for metastasis comes from studies on colon cancer,
here CSCs can be detected and prospectively enriched with a vari-
ty of cell surface antigen markers [48–52]. Three distinct types of
SCs (also referred to as tumor-initiating cells, TICs) are likely to
xist in colon cancer: extensive self-renewing long-term (LT-TICs),
umor transient amplifying cells (T-TAC), and delayed contributing
DC-TICs) [53]. Only self-renewing LT-TICs were shown to be able
o contribute to metastasis formation [53]. Finally, a more speciﬁc
arker of migratory and distant metastasis-causing CSCs in colon
ancer was recently identiﬁed: a subpopulation of CD26+ cells was
ound in both primary and metastatic tumors from advanced stage
RC patients capable of giving rise to CTCs in the portal vein and to
istant metastasis [54].
The above examples of heterogeneity in CSC populations, as well
s several others [55] are likely to reﬂect plasticity in the CSC pheno-
ype. Additional plasticity is also reﬂected in studies that show that
on-CSCs can acquire CSC properties [56,57]. For example, similar
o normal stem cells, a microenvironmental niche has been shown
o be required to maintain glioma and skin cancer CSCs [58,59],
nd this is probably also the case for other tumor types [60]. A
erivascular location can actually be the driving force that leads to
he acquisition of CSC properties by non-CSC subpopulations [61].
hus extrinsic microenvironmental cues are emerging as important
eterminants of the CSC population.
.4. Sleeping it off: dormancy
Metastases  can occur many years after surgical removal of the
rimary tumor, which has given rise to the concept of dormancy.
hese late-developing metastases are thought to develop from
TCs that have become re-activated after remaining in a stable dor-
ant state over a prolonged period [62]. For example, after radical
rostatectomy for prostate cancer, almost half of all patients have
etectable DTCs in their bone marrow more than 5 years after their
urgery [63]. Dormant tumor cells can exist in a quiescent state, or
s micrometastases in which proliferation is balanced by cell death
hrough apoptosis [7]. Reactivation of these dormant cells can beer Biology 22 (2012) 174– 186 177
due to changes in the tumor cells themselves, for example due to
loss of metastasis suppressor genes that regulate dormancy [64],
as well as to modiﬁcation of their microenvironment, for example
extracellular matrix (ECM) remodeling and recruitment of inﬂam-
matory cells [65,66]. The activation of the growth of indolent tumor
cells by bone marrow-derived cells (BMDC) recruited in response to
osteopontin produced by a second remote “instigator” tumor may
also reﬂect the re-animation of dormant cells [67]. Due to their
quiescence or slow turnover, dormant tumor cells are resistant to
conventional cytotoxic therapies because their intrinsic quiescence
makes them insensitive to DNA-damaging agents that speciﬁcally
target cycling cells [68].
An elegant recent study that looked at the mechanism behind
the re-activation of dormant breast cancer cells in the bone mar-
row provides evidence that intrinsic changes in gene expression
in tumor cells can relieve dormancy [41]. Metastases growing out
in the bone marrow after long latency periods were found to
express VCAM-1, in contrast to the parental clone that was  orig-
inally injected into the experimental animals. In further rounds of
injection into animals, these VCAM-1-expressing cells were able
to form bone metastases without entering dormancy. Mechanisti-
cally, VCAM-1 allows breast tumor cells to recruit 41-positive
osteoclast progenitors, thereby elevating osteoclast activity that
leads to bone destruction. These data nicely demonstrate that
in vivo evolution of tumor cells can lead to the loss of dormancy.
There  are a number of parallels between dormant tumor cells
and CSCs. As mentioned above, CSCs can be quiescent, and are
also resistant to chemotherapy. Mechanisms that CSCs share with
normal stem cells underlie their innate resistance to therapy, for
example multi-drug resistance due to up-regulation of cellular
efﬂux pumps [69,70], activation of the DNA damage response
[71], and lower concentrations of reactive oxygen species [72]. A
perivascular location regulates CSC identity (see above), and is also
required for the survival of dormant tumor cells that have dissem-
inated to the brain [73].
2.5.  Re-evaluating EMT: multiple functions in metastasis?
A  concept that continues to attract attention is the notion that
the morphogenetic program of EMT  becomes activated in can-
cer cells as they progress, and that this contributes to metastasis
formation. During the transition from benign adenoma to malig-
nant carcinoma and metastasis formation, differentiated epithelial
tumor cells are thought to acquire a de-differentiated, migra-
tory, and invasive phenotype through the process of EMT  [74].
This process of EMT  is accompanied by dramatic changes in
cellular morphology, the loss and remodeling of cell–cell and
cell–matrix adhesion, and the gain of migratory and invasive capa-
bilities [75,76]. The functional contribution of EMT  to metastasis
in patients is still debated, yet recent progress in the discovery of
novel EMT  markers provides increasing evidence for the occurrence
of EMT  in human cancers [19,77,78].
It is now becoming evident that EMT  itself is a multistage pro-
cess, involving distinct genetic and epigenetic alterations and a high
degree of cellular plasticity. In the past years, a large number of
genes have been identiﬁed that seem to be critical for this pro-
cess [75]. A major molecular event during EMT is the loss of the
epithelial cell–cell adhesion molecule E-cadherin, which by itself
can sufﬁce to induce EMT  and tumor progression [79–81]. Con-
versely, cells undergoing EMT  acquire expression of mesenchymal
markers such as vimentin.
A  broad-spectrum of transcriptional and post-transcriptional
regulators that have been implicated in malignant progression also
regulates EMT  [82]. Many growth factors such as transforming
growth factor  (TGF),  and their associated signal transduction
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epressors, such as Snail1 (Snail), Snail2 (Slug), Zeb1 (EF1), Zeb2
Sip1), E47, and Twist, which in turn repress a number of genes,
ncluding E-cadherin [75,83,84]. Many other transcription factors
lso play critical roles in EMT  [75,85]. Moreover, a number of
icroRNAs that are differentially expressed during EMT  are piv-
tal regulators of the complex circuits that underlie the multiple
tages of EMT  [86–88]. Furthermore, several enzymatic activities
nd factors critical for epigenetic regulation, such as DNA methy-
ation and histone modiﬁcations, are themselves modulated in
heir expression or activities during EMT  [89,90]. Together, these
hanges orchestrate the dramatic reprogramming of cells that char-
cterizes EMT.
Cell  polarity is regulated by the Scribble, the Partitioning defec-
ive (Par) and the Crumbs complexes [91]. Loss of apical-basal
olarity as a result of aberrant expression of polarity proteins is
onsidered a prerequisite for metastatic tumor progression and
eads to EMT. This is well illustrated by the Par complex that con-
ists of the proteins Par3, Par6 and the atypical protein kinase C
91]. TGF downregulates Par3 expression, revealing a mechanism
y which TGF can  disrupt tight junction formation, mediate loss
f apical-basal cell polarity and induce EMT  [92]. Par6 of the Par
omplex promotes tumor initiation and progression and interacts
ith the TGF receptor. Blocking the TGF-dependent phosphory-
ation of Par6 in breast cancer models reduces metastasis to the
ungs and highlights the importance of the loss of polarity sig-
aling for EMT  and metastasis [93]. Similarly, repression of the
rumbs polarity complex in epithelial tumors occurs concomitantly
ith increased expression of vimentin and reduced expression of
-cadherin, and its expression negatively correlates with the migra-
ory and metastatic capacity of cells. Importantly, the proteins ZEB1
nd Snail mediate repression of Crumbs, linking known regulators
f EMT  to polarity protein signaling through the Crumbs protein
94].
EMT appears not to be a unitary “black and white” process
hat leads invariably and irreversibly from a purely epithelial to a
urely mesenchymal phenotype; there appear to be shades of gray
n between [82,95]. It has suggested, for example, that EMT  should
e classiﬁed into three subtypes [95]. Furthermore, basal-like
reast carcinomas often exhibit features associated with EMT,
et retain some epithelial characteristics [96]. Such intermediate
tates have been referred to as the metastable EMT  phenotype [97].
oreover, there is also considerable plasticity in the response to
MT  induction, and is often a reversible process both physiologi-
ally and pathologically. For example, hypoxia induces a reversible
MT in breast cancer cells [98]. The reversibility of EMT  in the
ancer context has been used to suggest that EMT  allows cells
o invade and disseminate, and is then reversed at distant sites
hrough a mesenchymal–epithelial transition (MET) that results in
 metastasis that phenotypically resembles the originating primary
umor [19]. Evidence for dynamic reversible phenotypic changes
n vivo during dissemination has been obtained for melanoma [99].
utocrine motility factor [100] and expression of GATA3 [101]
ave been shown to reverse EMT. Partial EMT  has been shown to
ecrease cell adhesion but still allow collective cell migration [102],
onsistent with observations that the mesenchymal (single cell)
nd collective modes of migration are reversibly interchangeable
103,104]. These and other such dynamic reversible changes have
een suggested to be vital for dissemination [105]. The multiple
evels at which EMT  is regulated [82,106] provides a platform for
he ﬁne-tuning of metastable transitional states between purely
pithelial and purely mesenchymal phenotypes. The spatial and
emporal expression and combination of transcriptional repressors
hat are induced, for example, can inﬂuence the outcome of the
MT process [107]. Thus a picture emerges in which EMT  describes
 spectrum of phenotypes that are reversibly interchangeable and
ubject to dynamic regulation by the microenvironment. Dynamicer Biology 22 (2012) 174– 186
interchange  in the “gray scale” between purely epithelial and
purely mesenchymal phenotypes as evidenced by the interplay
between ZEB and miR-200 points to the importance of such
transitions in tumor progression [86].
Classically, the induction of EMT  has been interpreted as being
important in the process of metastasis by endowing tumor cells
with invasive properties. However, recent ﬁndings suggest that
EMT provides many more properties of relevance to metastasis
than just invasiveness. For example, EMT  serves as an escape route
for tumor cells from a variety of obstacles connected with cell
transformation and rapid tumor growth, including oncogene addic-
tion, oncogene-induced cellular senescence, tumor hypoxia, and
increased apoptosis [43,108,109]. Apparently, EMT  ensures that
cancer cells not only gain migratory and invasive capabilities but
also survive once they have left their accustomed primary tumor
environment. Signaling pathways elicited by the EMT  process pro-
vide a variety of survival signals that overcome cell cycle arrest and
cell death by apoptosis or anoikis that otherwise would be trig-
gered by the cytokine storm occurring within the primary tumor
environment, by the inﬂammatory responses within the neighbor-
ing tissue and by the immune defense within the blood circulation.
Accordingly, the genetic program of EMT  includes a variety of
immunosuppressive functions.
The  complex changes in the cytoskeleton associated with motil-
ity and invasiveness may  be incompatible with cell proliferation
[110]. Accordingly, it has been shown that growth arrest can be a
feature of EMT, for example through increased levels of p16ink4a
[111] and repression of cyclin D expression [112,113]. Consistently,
persistent expression of Twist has been associated with main-
tenance of dormancy and quiescence [107]. Conversely, MET is
associated with increased proliferation [86].
EMT  also appears to play a critical role in the generation and
maintenance of cancer stem cells, consistent with the observa-
tion that many stem cell genes are expressed in metastatic cancer
cells [114,115]. Indeed, EMT  increases the stemness of cells, as
after completion of EMT  cancer cells express many stemness mark-
ers, they are able to form spheroids in culture, they are more
tumorigenic in xenograft transplantation experiments and they are
more metastatic [114–116]. A broad spectrum of signals from the
tumor microenvironment may  trigger EMT  at the invasive front
of epithelial malignancies, where tumor cells are in direct con-
tact with stromal components such as ﬁbroblasts, myoﬁbroblasts,
granulocytes, macrophages, mesenchymal stem cells, and lympho-
cytes that are able to secrete diffusible EMT-inducing signals [117],
thereby inducing EMT, stemness properties, and facilitating detach-
ment and dissemination from the primary site [118,119]. Moreover,
quiescent stem-like cancer cells are earmarked by expression of
EMT  markers [75]. The ability of EMT  to induce both cell cycle arrest
and endow stemness properties on cells may  therefore by of rele-
vance to the quiescent CSC subpopulations mentioned above. The
induction of EMT  may  contribute to the plasticity in the CSC pheno-
type, for example, endowing non-CSCs with stemness properties.
However, the degree to which genetic programs that regulate stem-
ness and EMT  overlap remains to be properly investigated. EMT
has also been suggested to generate mCSCs that leave the primary
tumor and disseminate to distant sites, subsequently undergoing
MET to resume growth and form metastases that are phenotyp-
ically similar to the primary tumor from which they are derived
[19,86].
Finally, cells that have undergone EMT  are found to exhibit
increased resistance against many, but not all chemotherapeutic
agents [116]. Interestingly, the converse is also true: chemical enti-
ties have been found that eradicate with higher efﬁcacy cells that
have undergone EMT  as compared to their epithelial counterparts,
raising the possibility of directly targeting cells that have under-
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. Concepts of the soil
The  last few years have seen a dramatic increase in our knowl-
dge about key constituents of the microenvironmental “soil” that
upports the survival and outgrowth of the metastatic “seed” in
istant organs. It has become clear that the microenvironment
round  DTCs has a profound inﬂuence on whether they die, remain
ormant or grow as metastases [7]. Different tumor types may
ave different microenvironmental requirements for metastatic
utgrowth. Such differences may  contribute to differences in intrin-
ic metastatic potential, namely the tendency for some tumor types
e.g. melanomas) to form metastases even when the primary tumor
s very small, while other tumor types (e.g. basal cell carcinomas)
arely metastasize even after sizable growth of the primary tumor
6]. Similarly, particular microenvironmental requirements for the
urvival and growth of DTCs from different types of cancer may
nderlie organ-speciﬁc patterns of metastasis.
.1. Inﬂaming the situation: a niche occupation
A microenvironment that is conducive to the growth of DTCs
as been termed a metastatic niche [121]. Recent years have
een a number of seminal studies that have identiﬁed key con-
tituents of such niches. Remodeling of the ECM and recruitment of
nﬂammatory cells and other BMDC play a central role [122–125].
rowth factor, cytokines, chemokines and other proteins produced
y cellular components of the metastatic niche are pivotal in the
ormation of metastatic niches, for the attraction of CTCs, and
or the survival and outgrowth of DTCs [122–124,126]. A num-
er of observations also suggest that a perivascular location is
 pre-requisite for DTC survival and outgrowth [73], and there
s increasing evidence that hypoxia plays an important role in
he metastasis-promoting function of metastatic niches [126–128].
rogressive changes in the stroma of primary tumors takes place
uring tumor formation and progression [129,130], and there are
lso many similarities between these changes and the constituents
f metastatic niches.
Metastatic  niches may  be found endogenously in organs where
etastases form. A higher prevalence of such niches may  under-
ie the predilection of DTCs to grow as metastases in organs such
s lymph nodes, lungs, liver, brain and bone. A number of obser-
ations suggest that by occupying the normal stem cell niche, for
xample in the bone marrow, DTCs ﬁnd a primed niche that sup-
orts their growth [131,132]. Nevertheless, endogenous metastatic
iches are probably sparsely distributed, which may  account in part
or the inefﬁciency of the metastatic process. For example, injection
f tens of thousands of tumor cells intravenously only generates
everal hundred metastases, even after several rounds of selection
or the ability to grow as experimental metastases in the lungs after
ntravenous injection which would be predicted to highly enrich for
ells with metastasis-forming ability [133].
Remodeling of the organ microenvironment has been demon-
trated in recent years to create metastatic niches that foster
he outgrowth of DTCs. These niches can be induced by primary
umors prior to the settling of DTCs in organs – so-called pre-
etastatic niches – that can also attract CTCs through growth
actors, cytokines and other chemoattractants that are produced
y niche components [122–124]. In experimental models, pre-
etastatic niche formation has been shown to be critical for
he formation of fulminant metastases [122–124]. Formation of
etastatic niches after removal of the primary tumor, for exam-
le due to inﬂammatory processes, may  be responsible for the
e-activation of dormant DTCs, although experimental evidence to
upport this notion still remains to be garnered.
It is notable that many of the components of metastatic
iches  and their formation are related to inﬂammatory processes.er Biology 22 (2012) 174– 186 179
Pro-inﬂammatory members of the S100 family and members of
the Serum Amyloid A acute phase proteins have been identi-
ﬁed as having a pivotal role in the formation and function of
metastatic niches, playing a key role, for example, in the recruit-
ment of CD11b+ myeloid cells to these sites [134]. Monocyte
and macrophage-speciﬁc chemokines are also expressed [123].
The remodeling of the ECM (see below), such as the produc-
tion and deposition of ﬁbronectin and the activities of lysyl
oxidases and proteases, is a hallmark of both sites of inﬂamma-
tion and of pre-metastatic niches [135]. Hypoxia, an emerging
niche feature that also induces expression of lysyl oxidases, can
also promote inﬂammatory responses [136]. In addition to releas-
ing cells from dormancy in the bone [41], VCAM-1 expression
on tumor cells has also been recently shown to mediate their
interaction with metastasis-associated macrophages, providing a
survival advantage [137]. Taken together, these observations sug-
gest that the formation of metastatic niches recapitulates the
inﬂammatory processes and tumor–stroma interactions that drive
primary tumor growth, and thereby fosters metastasis formation
by DTCs.
3.2. Digging over the soil
Remodeling  of the ECM has emerged as an important event dur-
ing the establishment of metastatic niches. MMP-9, produced for
example by VEGFR1+ BMDC, is required for the formation of pre-
metastatic niches and the outgrowth of secondary tumors in the
lung [122,138]. Additional ECM components such as ﬁbronectin
[122], periostin [139] and tenascin-C [140] are produced in these
niches, and existing ECM components are modiﬁed, for example
through the activity of lysyl oxidases, enzymes that cross-link colla-
gen and elastin [126]. Together, these and other mechanisms serve
to modify the ECM, thereby creating a microenvironment that is
permissive for the growth of DTCs.
ECM remodeling may  act in a number of ways to promote
the outgrowth of metastases. Changes in the constituents of the
ECM can of course serve to modify epitopes with which integrins
and other receptors on the surface of tumor cells can interact.
Integrin-mediated activation of focal adhesion kinase (FAK) signal-
ing promotes cell survival and proliferation [141] and can regulate
CSC properties [142]. Remodeling of the ECM can also be sufﬁ-
cient to re-activate dormant tumor cells, for example mediated
by integrin-FAK signaling [65,143]. Induction of periostin expres-
sion by ﬁbroblasts in metastatic niches is required for recruitment
of Wnt  ligands and the maintenance of CSC properties in DTCs
[139]. Evidence is also emerging that an important outcome of
matrix remodeling is an increase in the stiffness or rigidity of
the microenvironment in a manner that can have a profound
effect on cell behavior. For example, matrix cross-linking medi-
ated by the activity of lysyl oxidases increases focal adhesion
formation and FAK activation, and promotes invasiveness and
malignancy [144]. Caveolin1 expression on carcinoma-associated
ﬁbroblasts (CAFs) remodels and stiffens the ECM microenviron-
ment, and consequently promotes metastasis formation [145].
Matrix stiffness also regulates the activity of the TAZ transcription
co-activator that forms part of the Hippo pathway [146], and TAZ
activity confers stemness properties on breast cancer cells [147].
In hepatocellular carcinoma cells, stiffer matrices were found to
promote proliferation and chemoresistance, while cells surviving
after chemotherapy on softer matrices exhibited a reversible dor-
mant phenotype associated with expression of CSC markers [148].
Finally, increased matrix stiffness favors TGF-induced EMT  over
apoptosis [149]. Thus a picture emerges in which enhanced matrix
stiffness maintains or endows CSCs properties on tumor cells, can
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.3. Long range fertilizers of the soil
A remarkable ﬁnding that has emerged from the study of the
ormation of pre-metastatic niches is the long-range signaling that
llows primary tumors to establish metastatic niche structures.
actors such as VEGF-A and PlGF produced by primary tumors act
istantly on the bone marrow to mobilize VEGFR1+ BMDC that
ontribute to pre-metastatic niche formation [122]. Similarly, pri-
ary tumor-derived VEGF-A, TNF and TGF induce expression of
100A8 and S100A9 in developing pre-metastatic niches, which in
urn recruits CD11b+ myeloid cells [123].
Recent studies have implicated primary tumor-derived
icrovesicles and exosomes in the long-range signaling involved
n pre-metastatic niche formation [150]. Microvesicles and exo-
omes contain membrane and cytoplasmic proteins, as well as
ucleic acids derived from the cell of origin. They can be trans-
orted via the blood, and the cargo they carry can interact with
arget cells and modify their behavior [151]. Exosomes released
rom rat pancreatic adenocarcinoma cells together with CD44v6
n the soluble fraction complement each other in generating a
iche for efﬁcient tumor outgrowth [152]. Microvesicles released
rom CD105-positive renal carcinoma CSCs stimulate angiogenesis,
pregulate VEGF-A, MMP2  and MMP9  expression in pre-metastatic
ites in the lung, and promote lung metastasis [153]. Microvesicles
ave also been shown to be involved in the bilateral communi-
ation between tumor cells and ﬁbroblasts, with tumor-derived
icrovesicles acting to upregulate MMP9  expression in ﬁbroblasts
154].
The requirement for long-range signals derived from primary
umors that orchestrate the formation of pre-metastatic niches
ay account for the association between elevated risk of metas-
asis development and increasing primary tumor size. It would
eem reasonable to assume that the tumor-derived growth factors
nd other signaling molecules involved would need to rise above
 given systemic concentration threshold before having an effect
n the bone marrow or potential sites of pre-metastatic niches.
arger tumors would be expected to produce more of the requi-
ite signaling molecules, and therefore the concentration of these
olecules in the circulatory system should also rise concomitantly.
hus a niche environment that supports the outgrowth of DTCs as
etastases may  only develop once the primary tumor reaches a
ufﬁcient size to produce enough signaling molecules to activate
iche formation.
.  Putting it all together: conﬂicting or compatible
oncepts?
As outlined above, a number of novel concepts have arisen
ecently as a result of new groundbreaking experiments, and exist-
ng concepts have also been modiﬁed as a result. These concepts
ften only consider one particular aspect of metastasis, and none
f them completely explain the process, nor account for all exper-
mental ﬁndings. Is it possible to synthesize a concept on the basis
f the data that has been generated to date that uniﬁes these dif-
erent concepts and provides a more comprehensive overview of
he process of metastasis? Some of the concepts above are appar-
ntly conﬂicting, for example regarding the question of whether
he metastatic dissemination that ultimately gives rise to metas-
asis is an early event after tumorigenesis or rather occurs late in
umor development. It is possible that no single concept explains
he process of metastasis, and that the mechanisms differ between
ancer types or even between individual patients. Nevertheless,
he process of metastasis is comparable for many different types
f cancer (local progression and invasion, transport in the circula-
ory system, extravasation, survival and growth at (often similar)er Biology 22 (2012) 174– 186
secondary  sites), suggesting that common mechanisms are prob-
ably operative. Furthermore, there are considerable similarities
between several of the concepts outlined above, which provide a
foundation for putting together the pieces of the metastasis concept
jigsaw puzzle.
Striking areas of convergence are the commonalities that have
emerged between the regulation of EMT, stemness, dormancy and
therapy resistance. Many of these are pointed out above. The sim-
ilarities between CSCs and cells that have undergone EMT  have
been recently extensively reviewed [110,116]. A further example
is provided by CXCR4. In addition to marking CSCs that will form
metastases, CXCR4 and its ligand SDF-1 have been implicated in
regulating EMT  in breast cancer [155], oral SCC [156] and pan-
creatic cancer cells [157], and probably act in conjunction with
TGF [158,159]. Similarly, CXCR4 is associated with chemoresis-
tance [160] and reversible dormancy [148].
It is also striking that many of the constituents that have been
described as being crucial for metastatic niche function serve to
regulate EMT, stemness, dormancy and therapy resistance. For
example, VEGF-A drives the formation of pre-metastatic niches
[122], creates a perivascular niche that maintains the stemness of
skin tumor CSCs [59] and suppresses dormancy [73]. EMT is induced
by inﬂammatory regulators that are present in metastatic niches
[161], as exempliﬁed by IL-1 in head and neck cancer [162]. The
ECM remodeling that typically occurs in inﬂammation and ﬁbrosis
is very similar to that found in metastatic niches, and contributes
to EMT  [95]. Consistently, the lysyl oxidase LOXL2 induces EMT
via increasing the stability and activity of Snail1 [163]. MMPs  are
also activated in the metastatic niche and induce EMT  [164]. The
metastatic niche constituent periostin regulates CSC properties, as
well as EMT  [165]. Hypoxia promotes CSC stemness, as well as
the formation of a CSC niche [166]. Furthermore, hypoxia is also
a potent and reversible inducer of EMT  [98], and a recent study
implicates it in inducing dormancy in glioblastoma CSCs [167].
5.  The stromal progression model
The above observations indicate that there is a tight intercon-
nection between EMT, stemness, dormancy and therapy resistance,
and it is likely that the metastatic niche plays a critical role in reg-
ulating these processes at sites where secondary tumors develop.
These and the other observations described above allow us to ten-
tatively suggest a concept of metastasis that we have called the
stromal progression model (Fig. 1). The tumor stroma is comprised
of ECM, non-malignant cells and the signaling molecules they pro-
duce. In the stromal progression model, progressive co-evolution
of the tumor stroma and the genetic make-up of tumor cells at both
the primary and secondary sites provide the platform required for
metastasis formation. This model accommodates many aspects of
the disparate models and theories that have been suggested to date,
and is outlined in detail in the following text.
Similar to clonal selection models, the stromal progression
model suggests that serial acquisition of genetic mutations and
aberrations driven by increasing genomic instability occurs in
tumor cells during primary tumor progression, together with epige-
netic changes. However, stromal progression also occurs in parallel,
for example the progressive remodeling of the ECM in the tumor,
activation and recruitment of stromal cells such as ﬁbroblasts and
BMDC, regional hypoxia, the induction of angiogenesis and the
development of an inﬂammatory milieu. Breach of the basement
membrane and subsequent invasion further exposes tumor cells
to new microenvironments and further stimulates stromal pro-
gression. Thus the dynamic stepwise mutual and interdependent
cross-regulation between tumor and stromal cells leads to pro-
gression of the tumor as a whole. In the absence of an appropriate
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Fig. 1. The stromal progression model. During the development of the primary tumor, progressive genetic and epigenetic changes take place in tumor cells (upper panel).
In  parallel, the stroma associated with the tumor cells also becomes progressively modiﬁed, for example through extracellular matrix remodeling and the activation and
recruitment of cells such as carcinoma-associated ﬁbroblasts (CAFs), tumor-associated macrophages (TAMs) and other cells of the immune system. For the sake of clarity, only
some  of these changes have been depicted. Interactions between the tumor stroma and tumor cells modify the stemness properties of the tumors cells, for example through
epithelial–mesenchymal and mesenchymal–epithelial-like transitions (EMT and MET), which regulates the cancer stem cell (CSC) subpopulation. Dissemination from the
primary  tumor begins early. Upon entering the secondary site, disseminated tumor cells (DTCs) have a number of possible fates, some of which are depicted in the left hand
side  box, bottom panel. These initial fates are determined by the underlying genetic and epigenetic status of the DTC, and through interactions with the microenvironment
at the secondary site. EMT- and MET-like transitions, further genetic progression in the tumor cells, and stromal progression in the microenvironment can subsequently
alter DTC fate and lead to the growth of overt metastases. Continuing mutual interactions between tumor cells and stromal cells at the secondary site stimulate stromal
progression, as in the primary tumor. Furthermore, as the primary tumor grows, increasing amounts of metastatic niche-inducing factors accumulate systemically, resulting















pite, as in the case of pre-metastatic niches that prime the microenvironment to su
ross-seeding between the primary tumor and its metastasis may  contribute to the
tromal compartment, the genetic and epigenetic changes in tumor
ells are insufﬁcient to support tumor growth and survival. Tumor
rogression is therefore built on a foundation of genetic and epi-
enetic changes in tumor cells, but is also absolutely dependent
n stromal progression in parallel (Fig. 1). An important result
f the interplay between tumor cells and the stroma is the gen-
ration of CSCs that drive tumor growth, whose properties are
etermined by their underlying genetic makeup, but also by the
icroenvironment, in a process that involves dynamic EMT  and
ET transitions that may  only be partial. These transitions also con-
ribute to tumor cell survival, and regulate dormancy, invasiveness
nd therapy resistance, and can occur in both CSC and non-CSC
opulations. This aspect of the stromal progression model has outgrowth of incoming DTCs. Self-seeding of the primary tumor or metastasis, or
ll make-up of the tumor cell population at the primary and secondary sites.
parallels  with the dynamic heterogeneity model proposed decades
ago [29].
Cancer cell dissemination begins early, for example after escape
from oncogene-induced senescence [43], and continues through-
out tumor growth and progression. CTCs leaving the tumor no
longer have contact with the supportive stromal microenviron-
ment they are accustomed to, and the genetic and epigenetic
changes they carry are usually insufﬁcient to support their sur-
vival or growth as a fulminant metastasis. An appropriate stromal
compartment therefore has to be re-established at secondary sites
if DTCs are to survive and grow out as metastases. DTCs that do
not end up in an appropriate microenvironment (or which can-
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egressing. If the microenvironment supports the survival of the
TCs, or is modiﬁed to support their survival, then the DTCs can
ontinue to acquire genetic mutations and aberrations at sec-
ndary sites, and progress genetically in parallel to tumors cells in
he primary tumor, as foreseen in the parallel progression model.
owever, concurrent stromal progression also accompanies these
enetic changes in the tumor cells at the secondary site, similar to
he case in the primary tumor (Fig. 1).
Stromal progression also takes place at secondary sites to form
icroenvironments that support outgrowth of metastases. Such
icroenvironments may  be initiated and developed in a number
f conceivable ways: (i) DTCs may  settle in pre-existing microen-
ironments that provide stromal components they need. These
ay be normal stem cell niches, for example, or pre-metastatic
iches induced by the primary tumor. (ii) Factors produced by the
TCs themselves may  act on the surrounding stroma and initiate
r contribute to the stromal progression that ultimately supports
econdary tumor growth. Thus genetic changes in tumor cells can
romote stromal progression. (iii) Tumor–stroma interactions in
he primary tumor produce increasing quantities of soluble fac-
ors as the tumors grow, such as growth factors, cytokines and
hemokines. These begin to accumulate systemically and ulti-
ately induce the formation of metastatic niches as described
bove, either pre-metastatically or after the dissemination of DTCs.
ence the size of the primary tumor correlates with the incidence
f metastasis, as size is proportionate to the amount of factors
roduced. (iv) Once a primary tumor has been removed, parallel
enetic progression in the DTCs and/or associated stromal progres-
ion may  eventually lead to outgrowth of metastases. In addition,
ther pathological events such as tissue trauma or chronic inﬂam-
ation may  release sufﬁcient systemic levels of growth factors
nd cytokines that induce metastatic niche formation such that
etastatic niche formation is kick-started and/or stromal pro-
ression is supported. Removal of the primary tumor may  also
emove circulating factors that were repressing distant metastatic
utgrowth, such as angiogenesis inhibitors or matrix remodeling
nzymes.
In the stromal progression model, formation of (pre)metastatic
iches can constitute an important component of the stromal
emodeling required at secondary sites for the outgrowth of metas-
ases (Fig. 1). As in the primary tumor, the interaction of tumor cells
ith the stromal microenvironment at these sites plays a key role
n regulating metastable EMT–MET-like transitions that determine
temness properties, control dormancy, provide survival functions
nd modulate resistance to therapy. Thus EMT  can endow CSCs in
he primary tumor with migratory properties that can be reversed
t secondary sites through MET  in response to a new microen-
ironment, as has been suggested [19]. In the absence of MET,
hese cells may  remain dormant due to the quiescence-promoting
ffects of EMT. Similarly, non-CSC DTCs that survive may  eventu-
lly acquire stemness properties, for example through epigenetic
hanges in response to EMT  induced when an appropriate stromal
nvironment develops, and/or through genetic changes. Hence the
roperties of the tumor cells, the nature of the surrounding stroma,
he interaction between the two compartments, and the continu-
ng interdependent progressive evolution of the tumor cells and the
umor stroma act together to determine the stemness properties
equired for the outgrowth of metastases, regulate the re-activation
f dormant cells and determine sensitivity to therapy. Like pri-
ary tumors, metastases may  disseminate cells, and cross-seeding
etween primary tumor and their metastases may  contribute to
he similarities between them that are observed histologically and
n transcriptomic studies.
The  stromal progression model suggests that the sparse exis-
ence of appropriate endogenous stromal microenvironments that
re able to support tumor growth contributes to the low efﬁciencyer Biology 22 (2012) 174– 186
of  metastasis formation in experimental metastasis assays. This
may also be a reason why large numbers of cells are required
to get an efﬁcient “take rate” in experimental animals, and why
providing constituents of a supportive stroma, for example in the
form of Matrigel, increases take rate. The model also provides an
explanation for why continuous passaging of tumor cells in experi-
mental animals and selection for growth in particular organs would
give rise to tumor cells that metastasize efﬁciently to the organ
in question. Here, tumor cells are selected that have the ability to
interact with particular stromal microenvironments of the organ
concerned, to induce stromal progression in those microenviron-
ments, and/or to undergo genetic or epigenetic changes in response
to the endogenous or induced microenvironment.
6. Concepts and clinical perspectives
While the stromal progression model incorporates many
theories, observations and experimental ﬁndings, several open
questions remain. Major issues include the timing of dissemina-
tion of the metastatic seed, the degree to which the regulation of
stemness properties overlaps with the pathways that control EMT,
dormancy and therapy resistance, key stages in stromal progres-
sion, and the mutual interdependence between genetic changes in
cancer cells and changes in the associated stroma. Understanding
how metastasis works is of more than just academic interest, as an
accurate conceptual grasp of the process is fundamental to effec-
tive therapy. For example, if the tumor cells that seed metastases
disseminate late, a window of opportunity opens to remove the
primary tumor before metastatic deposits have taken root. If on
the other hand, early dissemination and parallel progression is the
overriding mode of metastatic seeding, then at the time of cancer
diagnosis, DTCs with the potential to develop into metastases will
already be present, and therefore the therapeutic strategy will need
to be different. Another implication of parallel progression is that
the choice of targeted therapies to treat metastases should be based
on molecular and biological features observed in metastases rather
than in primary tumors [22].
The dormancy of DTCs over long periods of time and their rel-
ative stability, together with relapse occurring many years after
diagnosis, surgery and initial treatment demands that more effort
is placed on understanding the regulation of dormancy. This may
provide a novel opportunity to prevent metastatic outgrowth and
keep disseminated cancer as a dormant, chronic but manageable
disease. Key issues are to understand how quiescent, disseminated
cancer cells interact with the microenvironment, and to deﬁne the
critical cues that awake cancer cells form dormancy and allow them
to progress to full metastasis.
Understanding  the nature of the tumor cells that initiate metas-
tases could be key to successful therapy. If metastases are seeded
by particular CSC subpopulations, then targeting them would be
expected to effectively suppress metastasis formation. The expres-
sion on CSCs of speciﬁc members of the family of CXC chemokines
receptors has recently received interest in this regard. Chemokines
serve as chemoattractants for cells endowed with CXC recep-
tors such as CXCR4 and CXCR1 that have been found to earmark
migratory subpopulations of CSCs in pancreatic and breast cancer,
respectively [47,168]. Selective blockade of CXCR1 targets breast
CSCs in human xenografts slow down primary tumor growth and
reduce metastasis formation [169]. Clinical trials with pharma-
cological inhibitors and monoclonal antibodies directed against
speciﬁc CXCRs will assess their capacity to block CSCs dissemina-
tion and prevent metastasis formation in cancer patients. These
and similar studies may  provide novel therapeutic strategies to
selectively target cancer CSCs after dissemination throughout the
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As pointed out above, the genetic disparity between primary
umors and their metastases suggests that analysis of the primary
umor may  not be the best way to determine appropriate treatment
f metastatic disease. CTCs represent tumor cells that have left the
rimary tumor and are also likely to be derived from metastases, so
here is growing interest in monitoring CTC as cellular surrogates
f metastatic dissemination [170]. DTCs are much less accessible
han CTCs, and can be less informative [171].
While CTCs can be detected in the blood of patients with many
ypes of solid cancer, they are best characterized in breast can-
er patients and most of our knowledge on CTCs is derived from
reast cancer [172,173]. Strong evidence indicates that the number
f CTC before treatment is an independent predictor of progression-
ree survival and overall survival in patients with metastatic breast
174] or prostate [175] cancers. Subsequently it has been shown
hat detection of even rare CTCs is associated with an increased
isk of metastatic progression and reduced survival in newly diag-
osed breast cancers [176,177]. A clinical challenge here is to deﬁne
hether CTC can be developed as reliable surrogate marker of
elapse and progression to metastasis for individual patients with
rimary breast cancer undergoing adjuvant treatments. Several
linical trials are currently addressing this question [173]. Another
qually challenging and relevant issue relates to the potential clin-
cal use of CTC as biomarker to predict response to therapy in
etastatic cancers. Initial evidence indicates that this might be the
ase in breast cancer, as persisting elevated counts of CTC during
herapy predicts shorter progression-free survival and precedes
adiological signs of progression [178]. Additional studies are in
rogress [173].
While  cumulating evidence indicates that CTC counts have
rognostic and predictive clinical signiﬁcance, many important
uestions on the biology of CTCs remain unanswered. For exam-
le, what is the best method to detect CTCs? CTCs are rare in the
eripheral blood (ranging from one to hundreds of cells per ml)
nd reliable detection/isolation is still challenging [179]. Available
ethods are mostly based on immunomagnetic isolation using
ntibodies directed against the epithelial cell surface molecule
pCAM (such as the commercially available and FDA-approved sys-
em CellSearch®), followed by immunocytochemistry staining for
pithelial markers (e.g. CK 8, 18, 19) [173]. As some CTCs undergo
MT, this approach may  miss an important CTC subpopulation.
imilar arguments also apply to the analysis of DTCs. Thus, novel
nrichment strategies including EMT  markers need to be devel-
ped.
A second crucial question is whether all detected CTCs are
otentially able to colonize distant organs and form metastases.
n other words, is the number of CTCs sufﬁcient to predict metasta-
is, or should additional biological and molecular parameters also
e considered? Determining viability, proliferation and expression
f EMT or stem cell markers may  already improve the prognos-
ic/predictive power of CTC, but the ultimate test would be to
irectly evaluate the metastatic capacity of individual CTCs in lab-
ratory assays.
A  third outstanding issue is whether CTCs represent a more
ppropriate cell population to deﬁne therapeutic strategies, com-
ared to cancer cells in the primary tumor, which are currently
sed for this purpose. The relevance of this point is exempliﬁed
y the detection of HER-2-positive CTCs in patients with HER-2-
egative primary breast cancer and, conversely, HER-2-negative
TCs in patients with HER-2-positive tumors [180–182]. CTCs may
lso be used, for example, to validate the activity of targeted anti-
ancer drugs, for instance by monitoring the phosphorylation state
f kinases targeted by the drugs or their downstream effectors
183].
In summary, clinical and basic research into the underlying
echanism of metastasis has in the last few years unearthed manyer Biology 22 (2012) 174– 186 183
new  facets of the process that results in the formation of secondary
cancers. While we  are still some way  from a complete under-
standing of the metastatic process, it is clear than many of the
contemporary models and theories that have arisen as a result of
these new ﬁndings are starting to converge. The stromal progres-
sion model we suggest here integrates many of these ideas. The next
few years will see exciting further progress that will provide us with
an increasingly accurate concept of how metastasis works, which
in turn will allow rational and effective therapies for metastatic
disease to be developed.
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